323 related articles for article (PubMed ID: 19795581)
1. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
2. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
Patel JD
Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
[TBL] [Abstract][Full Text] [Related]
4. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
8. Targeting epidermal growth factor receptor in head and neck cancer.
Ford AC; Grandis JR
Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cells.
Bonner JA; Buchsbaum DJ; Rogers BE; Grizzle WE; Trummell HQ; Curiel DT; Fiveash JB; Ove R; Raisch KP
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):950-8. PubMed ID: 14967455
[TBL] [Abstract][Full Text] [Related]
10. EGF receptor in lung cancer: a successful story of targeted therapy.
Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
12. Molecular selection for therapy of patients with non-small-cell lung cancer and impaired performance status: has the time come?
Lara PN
Clin Lung Cancer; 2006 Jan; 7(4):232-4. PubMed ID: 16512975
[No Abstract] [Full Text] [Related]
13. Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Kim DW; Choy H
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):11-20. PubMed ID: 15142630
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor biology (IMC-C225).
Kim ES; Khuri FR; Herbst RS
Curr Opin Oncol; 2001 Nov; 13(6):506-13. PubMed ID: 11673692
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a target to improve treatment of lung cancer.
Andratschke NH; Dittmann KH; Mason KA; Fan Z; Liao Z; Komaki R; Ang KK; Milas L
Clin Lung Cancer; 2004 May; 5(6):340-52. PubMed ID: 15217533
[TBL] [Abstract][Full Text] [Related]
17. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Saba NF; Khuri FR; Shin DM
Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
[TBL] [Abstract][Full Text] [Related]
18. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
19. Biology of interactions: antiepidermal growth factor receptor agents.
Harari PM; Allen GW; Bonner JA
J Clin Oncol; 2007 Sep; 25(26):4057-65. PubMed ID: 17827454
[TBL] [Abstract][Full Text] [Related]
20. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
Saijo N
Nat Clin Pract Oncol; 2005 Jun; 2(6):275. PubMed ID: 16264964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
